The permitted product is the generic model of Lotemax SM Ophthalmic Gel, initially developed by Bausch & Lomb. Lupin is the unique first-to-file applicant and is eligible for 180 days of generic drug exclusivity. The product might be manufactured at Lupin’s Pithampur facility in India.
Loteprednol Etabonate Ophthalmic Gel is a corticosteroid used to deal with irritation and ache following eye surgical procedure. Based on IQVIA MAT information from Might 2025, the reference product recorded estimated annual US gross sales of $29 million.
This improvement comes simply days after Lupin launched Prucalopride tablets within the US, following closing FDA approval. The drug is used to deal with power idiopathic constipation (CIC) in adults and is accessible in 1 mg and a pair of mg strengths. It’s bioequivalent to Motegrity tablets from Takeda Prescribed drugs U.S.A., Inc. The tablets might be produced at Lupin’s Goa facility. The estimated market dimension for Prucalopride tablets within the US is $184 million, in line with IQVIA MAT information for April 2025.
Additionally Learn: High 10 Nifty500 shares with dividend yields increased than business common
Lupin shares worth goal
Based on Trendlyne, the typical goal worth for Lupin stands at Rs 2,260, implying a 15% potential upside from present ranges. The inventory holds a ‘Purchase’ score from 26 analysts.Within the earlier session, Lupin shares closed 1.2% increased at Rs 1,961.3. Whereas the inventory has declined 17% year-to-date, it has gained 117% over the previous 12 months. Lupin’s present market capitalisation is Rs 89,575 crore.Additionally Learn: Avenue Favorite! 10 Nifty micro-cap shares analysts anticipate to rally as much as 60%
(Disclaimer: Suggestions, strategies, views and opinions given by the specialists are their very own. These don’t signify the views of the Financial Instances)
